logo
Warning over low funding to tackle invasive species damaging British wildlife

Warning over low funding to tackle invasive species damaging British wildlife

Independent11-05-2025
Less than 1% of the Government's biosecurity budget goes on invasive species, despite the danger they pose to British wildlife, figures suggest.
Conservationists warned the funding to tackle non-native plants and animals was failing to match the risk they posed to 'cherished' native species from water voles to ladybirds, as well as to waterways, homes, businesses and local green spaces.
They have called for more resources for border checks to stop non-native species arriving here, and funding for local groups to tackle the problem on the ground.
A freedom of information request to the Animal and Plant Health Agency by Wildlife and Countryside Link (WCL) shows only £2.47 million of the estimated £250 million biosecurity budget was going to tackling invasive species.
And just £250,000 of that was being channelled to local groups tackling non-native species on the ground – which range from Himalayan balsam and floating pennywort choking waterways to rhododendrons and giant blackberries strangling woodlands and grasslands, conservationists said.
The figures also show £22.7 million of the wider biodiversity budget – around 3% of the spend on protecting important habitats and species – was spent on tackling invasive species.
This funding is thought to be going towards areas such as tree disease ash dieback and Asian or yellow-legged hornets which pose a huge threat to honeybees and other insects, WCL said.
Spending on stopping the spread of yellow-legged hornets bucks the trend of low funding, the conservationists said – with more than £2.2 million spent over the last two years, compared to just under £500,000 in the same period on local action for wider invasive species.
Research has found that efforts to stop the yellow-legged hornets in the UK have delayed the insect's establishment when it has already taken hold in many countries.
But Wildlife and Countryside Link coalition of conservation groups said while this was a big achievement, the hornet, a voracious predator of other insects which first arrived in Europe on a shipment of pottery 20 years ago, was likely to establish here at some point.
And the high costs of tackling it shows the need to give greater border check powers and resourcing to stop these species arriving in the UK in the first place, the conservationists said.
The wildlife experts say invasive species play a major role in more than 60% of extinctions worldwide.
In the UK, species are in serious decline due to invasive species including water voles, preyed on by non-native mink, red squirrels, which face competition and disease spread from their grey cousins, and white-clawed crayfish that are under threat from North American signal crayfish.
Lisa Manning, policy officer at Wildlife and Countryside Link, said: 'Invasive species are one of the biggest risks to cherished species from water voles to ladybirds.
'They also wreak havoc on our waterways and cause damage to businesses, homes and to local parks and other green spaces.
'But the funding and support from the Government is failing to match the level of this threat,' she warned.
'We need more border check powers and resources to prevent new harmful species arriving.
'And more funding is needed to fight invasive species that have already arrived, so that local groups can stop struggling on an annual basis and take the long-term action needed for nature,' she urged.
Erin Shott, advocacy officer at Plantlife, said: 'Local groups and volunteers are putting up a great fight to halt the spread of invasive species.
'But this action needs further co-ordination and dedicated funding if we're to stop further damage to treasured local nature sites and native British wildlife.'
David Smith, from insect charity Buglife, said that despite the UK's success on yellow-legged hornets, 'we cannot afford to rely on reaction alone'.
'With many more invasive invertebrate species on the horizon, such as Chinese mystery snails, which can carry harmful parasites, and Asian longhorn beetles, which threaten our trees, timber, and fruit industries, there is a growing danger to both wildlife and the economy.
'We must focus on prevention rather than cure,' he said.
An Environment Department (Defra) spokesperson said: 'This Government will never waver in its duty to protect the UK's biosecurity.
'That's why we are bolstering our national biosecurity with a £200 million investment to set up a new National Biosecurity Centre and just last week announced £10 million of funding for cutting-edge surveillance projects to detect the spread of diseases and non-native species.'
An Animal and Plant Health Agency spokesperson said: 'Our teams work hard to tackle the threat of invasive non-native species, which cost the GB economy nearly £2bn a year, and help deliver a seamless border that maintains frictionless trade while protecting biosecurity.
'Members of the public who encounter invasive non-native species should report them following instructions on the Non-Native Species Secretariat website.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

The new stage four cancer treatments and what they mean for patients
The new stage four cancer treatments and what they mean for patients

Telegraph

timean hour ago

  • Telegraph

The new stage four cancer treatments and what they mean for patients

A stage-four cancer diagnosis once sounded like the end of the road – after all, there is no stage five. When Joe Biden's prostate cancer was recently labelled 'aggressive' and described as having spread to his bones, many assumed the worst. Yet today, thanks to astonishing advances in cancer science, a stage-four label need not mean imminent death. 'Stage four means the cancer has spread to another part of the body further away from where it started,' explains Dr Ben O'Leary, a clinical oncologist at the Royal Marsden and a researcher at The Institute of Cancer Research (ICR). 'Most stage-four cancers still can't be cured, but our deeper understanding of how cancers evolve and grow means many people are living longer. In some cases, we now see responses, and yes, even cures, that weren't thought possible 10 years ago.' What's driving this optimism? Five types of cancer offer a snapshot of progress. Skip to: Prostate cancer Blood cancers Breast cancer Bladder cancer Lung cancer Prostate cancer By the age of 80, half of men harbour cancer in their prostate, though it proves fatal in only a small minority. Even so, around 12,000 men die of metastatic prostate cancer each year in the UK. Dr Anna Wilkins of the ICR and Royal Marsden says metastatic prostate cancer most often spreads to the bones. 'On scans, you can see up to 50 spots all over the skeleton. But there has been big progress in new drugs.' Total testosterone blockade Standard treatment reduces testosterone, the hormone that fuels tumour growth. Abiraterone, developed at the ICR, goes further by blocking its precursor hormones, extending survival significantly. Liquid radiotherapy This exciting development involves injecting patients with a radioactive liquid. Cancer cells 'drink' more of the liquid than healthy cells and the resulting burst of radiation destroys bone metastases. Liquid radiotherapy drug Radium-223 is already available on the NHS, while the even more potent Lutetium-177 PSMA is available privately and awaiting National Institute of Health and Care Excellence (Nice) appraisal. Multimodal first strikes 'We now combine hormone drugs – and sometimes chemotherapy – immediately after diagnosis,' says Dr Wilkins. Even resistant cancers respond to this approach. Treating the original tumour with radiotherapy, even in metastatic cases, also boosts survival: 'It's as if you're silencing a mothership that coordinates the metastases,' she says. While there is no cure yet, Dr Wilkins says, these approaches are turning stage-four prostate cancer into a condition many men will live with, not die from.

New brain scanner trialled in Kent could speed up dementia diagnosis
New brain scanner trialled in Kent could speed up dementia diagnosis

BBC News

time4 hours ago

  • BBC News

New brain scanner trialled in Kent could speed up dementia diagnosis

A pioneering brain scanner, one of the first to be owned by an NHS trust in England, is being trialled in Kent to improve dementia diagnosis and mental health research. The low-field MRI scanner is smaller, cheaper, and more portable than traditional machines, and could be used in community clinics for faster, more accessible by the Kent and Medway NHS and Social Care Partnership Trust (KMPT), with academic partners, the research aims to combine the scanners with AI to match the image quality of standard MRI scans. Prof Sukhi Shergill, from KMPT, believes the scanner could be "revolutionary" and lead to quicker dementia diagnosis. He said it was "currently one of the biggest challenges we face in healthcare".Experts say low-field scanners have the potential to replace standard brain scanning techniques and transform early diagnosis and treatment strategies for mental health MRI scanners often require specific power and cooling infrastructure and are sensitive to vibrations and some magnetic fields, which means they are usually housed in specially designed hospital new scanners produce lower quality images but combined with AI software they are capable of matching the image quality of larger, more expensive machines. In his role as director of research for KMPT and co-director of research at KMMSS, Prof Shergill said having smaller scanners in local communities meant they could access "almost everybody in Kent"."It's a revolutionary kind of idea to go to put these low field scanners much more locally to people," he said. It is hoped the trials would also be a be a "significant step forward in speeding up dementia assessments".Dr Joanne Rodda, a senior lecturer at Kent and Medway Medical School (KMMS) and consultant psychiatrist at KMPT, is researching the scanners' ability to help with early diagnosis of said: "Low-field scanners could potentially be offered more widely, like in community memory clinics, providing more timely results, improving patient experience." The collaboration between KMPT, KMMS, and Canterbury Christ Church University aims to support innovative research to enhance the health and well-being of communities in Kent and Medway.

French pharma giant swoops on British vaccine champion in $1.6bn deal
French pharma giant swoops on British vaccine champion in $1.6bn deal

Daily Mail​

time4 hours ago

  • Daily Mail​

French pharma giant swoops on British vaccine champion in $1.6bn deal

French pharmaceuticals giant Sanofi has agreed to acquire privately-owned British biotech firm, Vicebio, in a deal worth up to $1.6billion (£1.2billion). The deal sees Sanofi take control of Vicebio's early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). London-based Vicebio says it is 'redefining how the world combats respiratory diseases', with its 'Molecular Clamp' tech enabling the development of next-generation vaccines that offer 'broad protection, ready-to-use formulations, and high manufacturability'. Vicebio's vaccine candidate complements Sanofi's existing range, and allows it to offer a wider range to doctors and patients. The French group said on Tuesday it would pay an initial $1.15billion for the London-based respiratory diseases specialist, with a further $450million in milestone payments to be paid based on development and regulatory progress. Sanofi will also gain Vicebio's molecular clamp tech, which is used to help an immune system to recognise and respond to viral proteins more quickly. The acquisition is expected to close in the fourth quarter of 2025. Sanofi says it won't have a significant impact on its 2025 financial guidance. Jean-François Toussaint, global head of research and development vaccines at Sanofi, said: 'Vicebio's Molecular Clamp technology introduces a purposefully simple but thoughtful approach to further improve vaccine designs at a time when respiratory viral infections continue to impact millions globally. 'This acquisition furthers Sanofi's dedication to vaccine innovation with the potential to develop next-generation combination vaccines that could provide protection to older adults against multiple respiratory viruses with a single immunisation.' The acquisition follows a number of recent purchases by Sanofi, following Vigil Neuroscience in May and the DR-0201 cell engager from Dren Bio in March. rMost recently, Sanofi completed its acquisition of Blueprint Medicines last month. Emmanuel Heron, chief executive of Vicebio, said: 'Their global scale and deep expertise in vaccine development provide the ideal environment to fully realize the potential of our innovative technology. 'We look forward to advancing our platform and pipeline to deliver meaningful benefits for patients and public health.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store